NovoCure Ltd. PT receives Investment Bank Analyst Rating Update
NovoCure Limited is an oncology company. The Company is principally engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. TTFields therapy is a treatment that uses electric fields tuned to specific frequencies to disrupt cancer cell division. TTFields therapy is delivered through a portable medical device. Optune is approved by the United States Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Optune Lua is approved by the FDA for the pathway for the treatment of malignant pleural mesothelioma (MPM) together with standard chemotherapies. It markets its products to United States, European Union, Germany, Japan and certain other countries.
|Average||104.43 (+14.88% Upside)|
|No. of Analysts||7|